bortezomib,pomalidomide,nirogacestat,teclistamab,daratumumab,lenalidomide
takeda,genmab,springworks therapeutics,janssen,bms
['daratumumab', ' lena', 'mmsm', 'majestec-2', 'majestec,(-majestec-1),(-majestec1),(-majestec 1),(-majestec-3),(-majestec3),(-majestec 3),(-majestec-i),(-majestec i),(-majesteci)', 'lenalidomide', 'multiple myeloma', 'teclistamab']
findings from the phase 1b majestec-2 trial showed that teclistamab plus with daratumumab and lenalidomide demonstrated potential for deep and durable responses in relapsed or refractory multiple myeloma. #mmsm #ash22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.